ITTO20060239A1 - Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare - Google Patents
Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolareInfo
- Publication number
- ITTO20060239A1 ITTO20060239A1 IT000239A ITTO20060239A ITTO20060239A1 IT TO20060239 A1 ITTO20060239 A1 IT TO20060239A1 IT 000239 A IT000239 A IT 000239A IT TO20060239 A ITTO20060239 A IT TO20060239A IT TO20060239 A1 ITTO20060239 A1 IT TO20060239A1
- Authority
- IT
- Italy
- Prior art keywords
- formulation
- oral administration
- health effects
- activity
- lowering
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 abstract 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 235000013793 astaxanthin Nutrition 0.000 abstract 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract 1
- 229940022405 astaxanthin Drugs 0.000 abstract 1
- 239000001168 astaxanthin Substances 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 abstract 1
- 229940093265 berberine Drugs 0.000 abstract 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 229940057059 monascus purpureus Drugs 0.000 abstract 1
- 229960001109 policosanol Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000239A ITTO20060239A1 (it) | 2006-03-30 | 2006-03-30 | Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare |
| AT07735308T ATE547098T1 (de) | 2006-03-30 | 2007-03-29 | Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt |
| ES07735308T ES2382115T3 (es) | 2006-03-30 | 2007-03-29 | Formulación oral con efectos cardiovasculares beneficiosos, que comprende berberina |
| PL07735308T PL2007429T3 (pl) | 2006-03-30 | 2007-03-29 | Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę |
| DK07735308.4T DK2007429T3 (da) | 2006-03-30 | 2007-03-29 | Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin |
| PT07735308T PT2007429E (pt) | 2006-03-30 | 2007-03-29 | Formulação oral com efeitos cardiovasculares benéficos, compreendendo berberina |
| EP07735308A EP2007429B1 (en) | 2006-03-30 | 2007-03-29 | Oral formulation with beneficial cardiovascular effects, comprising berberine |
| US12/295,616 US9623108B2 (en) | 2006-03-30 | 2007-03-29 | Formulation for oral administration with beneficial effects on the cardiovascular system |
| PCT/IB2007/051109 WO2007113748A1 (en) | 2006-03-30 | 2007-03-29 | Oral formulation with beneficial cardiovascular effects, comprising berberine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000239A ITTO20060239A1 (it) | 2006-03-30 | 2006-03-30 | Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITTO20060239A1 true ITTO20060239A1 (it) | 2007-09-30 |
Family
ID=38421558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000239A ITTO20060239A1 (it) | 2006-03-30 | 2006-03-30 | Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9623108B2 (it) |
| EP (1) | EP2007429B1 (it) |
| AT (1) | ATE547098T1 (it) |
| DK (1) | DK2007429T3 (it) |
| ES (1) | ES2382115T3 (it) |
| IT (1) | ITTO20060239A1 (it) |
| PL (1) | PL2007429T3 (it) |
| PT (1) | PT2007429E (it) |
| WO (1) | WO2007113748A1 (it) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100242345A1 (en) | 2006-05-19 | 2010-09-30 | LS9, Inc | Production of fatty acids & derivatives thereof |
| US8110670B2 (en) | 2006-05-19 | 2012-02-07 | Ls9, Inc. | Enhanced production of fatty acid derivatives |
| EP3483265B1 (en) | 2008-05-16 | 2021-07-21 | Genomatica, Inc. | Methods and compositions for producing fatty acids and fatty alcohols |
| ITMI20081403A1 (it) | 2008-07-29 | 2010-01-30 | Velleja Res Srl | Composizioni comprendenti berberina e/o suoi analoghi o estratti che la contengano, per la prevenzione e il trattamento delle alterazioni del quadro lipidico e glucidico |
| US8999686B2 (en) | 2008-10-28 | 2015-04-07 | REG Life Sciences, LLC | Methods and compositions for producing fatty alcohols |
| EP2405755A4 (en) * | 2009-03-11 | 2012-11-28 | Xintria Pharmaceutical Corp Inc | METHOD AND COMPOSITIONS FOR TREATING METABOLISM AND CARDIOVASCULAR DISEASES |
| WO2010126891A1 (en) | 2009-04-27 | 2010-11-04 | Ls9, Inc. | Production of fatty acid esters |
| FR2950061B1 (fr) | 2009-09-11 | 2013-12-20 | Coatex Sas | Monomeres associatifs a base de polycosanols, epaississants associatifs correspondants et leurs utilisations |
| KR101307051B1 (ko) | 2011-05-20 | 2013-09-11 | 강릉원주대학교산학협력단 | 미세조류 단백질 가수분해물을 포함하는 콜레스테롤 강하용 조성물 |
| ITMI20121696A1 (it) * | 2012-10-09 | 2014-04-10 | Ddf Group S A S | Composizioni per il trattamento delle iperlipidemie |
| ITMI20130241A1 (it) | 2013-02-21 | 2014-08-22 | Andrea Rondi | Composizione per il trattamento di disordini metabolici |
| ITUB20150541A1 (it) * | 2015-03-03 | 2016-09-03 | Acraf | Composizione comprendente sostanze e/o estratti naturali |
| PL3270707T3 (pl) | 2015-03-16 | 2021-05-31 | Nature's Sunshine Products Inc. | Fitokompleksy wykazujące wiele synergistycznych działań antyoksydacyjnych |
| EP3117825A1 (en) * | 2015-07-16 | 2017-01-18 | Rottapharm S.p.A. | Oral formulation comprising berberine and morus alba extract |
| IT201900020316A1 (it) * | 2019-11-04 | 2021-05-04 | Alesco Srl | Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico |
| IT201900020300A1 (it) * | 2019-11-04 | 2021-05-04 | Alesco Srl | Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie |
| WO2021090214A2 (en) * | 2019-11-04 | 2021-05-14 | Alesco S.R.L. | Sucrosomial® berberine, its compositions and their use |
| IT201900020290A1 (it) * | 2019-11-04 | 2021-05-04 | Alesco Srl | Berberina sucrosomiale®, sue composizioni e loro uso |
| IT202200008534A1 (it) * | 2022-04-29 | 2023-10-29 | Neilos S R L | “Composizione nutraceutica o farmaceutica per la salute cardiovascolare” |
| IT202200008537A1 (it) * | 2022-04-29 | 2023-10-29 | Neilos S R L | “Composizione nutraceutica o farmaceutica per la salute cardiovascolare” |
| DE202023106947U1 (de) | 2023-11-23 | 2024-01-10 | Supett Laboratories Limited | Zusammensetzung umfassend Panthenol, PQQ und Quercetin zur Vorbeugung von Herzkrankheiten |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952393A (en) | 1998-02-12 | 1999-09-14 | Sorkin, Jr.; Harlan Lee | Composition for reducing serum cholesterol levels |
| US6436406B1 (en) | 2000-06-15 | 2002-08-20 | A. Glenn Braswell | Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
| AUPR510001A0 (en) * | 2001-05-18 | 2001-06-14 | Jupitar Pty Ltd | Formulation and method |
| US20030054978A1 (en) | 2001-08-31 | 2003-03-20 | Babish John G. | Arginine compositions for coordinate modification of multiple cardiovascular risk factors |
| CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
| ITTO20040682A1 (it) * | 2004-10-07 | 2005-01-07 | Rottapharm S R L | Formulazione per somministrazione orale avente un effetto salutistico sull'apparato cardiovascolare |
-
2006
- 2006-03-30 IT IT000239A patent/ITTO20060239A1/it unknown
-
2007
- 2007-03-29 PT PT07735308T patent/PT2007429E/pt unknown
- 2007-03-29 US US12/295,616 patent/US9623108B2/en not_active Expired - Fee Related
- 2007-03-29 AT AT07735308T patent/ATE547098T1/de active
- 2007-03-29 EP EP07735308A patent/EP2007429B1/en active Active
- 2007-03-29 DK DK07735308.4T patent/DK2007429T3/da active
- 2007-03-29 PL PL07735308T patent/PL2007429T3/pl unknown
- 2007-03-29 WO PCT/IB2007/051109 patent/WO2007113748A1/en not_active Ceased
- 2007-03-29 ES ES07735308T patent/ES2382115T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090136469A1 (en) | 2009-05-28 |
| ATE547098T1 (de) | 2012-03-15 |
| EP2007429B1 (en) | 2012-02-29 |
| PT2007429E (pt) | 2012-04-12 |
| DK2007429T3 (da) | 2012-05-29 |
| PL2007429T3 (pl) | 2012-07-31 |
| EP2007429A1 (en) | 2008-12-31 |
| ES2382115T3 (es) | 2012-06-05 |
| WO2007113748A1 (en) | 2007-10-11 |
| US9623108B2 (en) | 2017-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE547098T1 (de) | Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| MX338515B (es) | Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio. | |
| CY1108794T1 (el) | Σπειροκυκλικα παραγωγα κυκλοεξανιου | |
| NZ606589A (en) | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| CL2007002095A1 (es) | Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado. | |
| EP2349279A4 (en) | MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF | |
| EP3626253A3 (en) | Stable formulations of linaclotide | |
| EA201001285A1 (ru) | Применение 25-oh d3 для воздействия на физиологию мышц человека | |
| TW200800987A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| GEP20166488B (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX365313B (es) | Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona. | |
| UY29395A1 (es) | Formulación de medicamentos conteniendo vardenafilo. | |
| CY1108314T1 (el) | Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος | |
| UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе | |
| MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| CL2012003250A1 (es) | Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto. | |
| HK1209027A1 (en) | Vesicular formulations, uses and methods | |
| WO2015021387A3 (en) | Formulations for control and prevention of periodontal and perimplant diseases and other diseases and conditions of the mouth, and supra and sub-gingival delivery methods and systems for such formulations | |
| WO2008120766A1 (ja) | 鎮痛用組成物 | |
| WO2011092655A3 (en) | Mentha suaveolens essential oil and therapeutic activities thereof | |
| IT1406221B1 (it) | Composizione contenente resveratrolo l/triptofano acido l/aspartico e vitamina b3 (nad+) per l'impiego in campo farmaceutico nutrizionale e cosmetico | |
| MY184940A (en) | Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent |